Last reviewed · How we verify

NCT05404217

Clinical Trial to Investigate the Efficacy and Safety of LN-OS-22 on Oxidative Stress and Systemic Inflammation in Overweight and Obese Population.

Completed NA Last updated 6 April 2023
What this trial tests

NA trial testing LN-OS-22 in Oxidative Stress in 64 participants. Completed in 13 March 2023.

Timeline
16 June 2022
Primary endpoint
13 March 2023
13 March 2023

Quick facts

Lead sponsorVedic Lifesciences Pvt. Ltd.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeother
Enrollment64
Start date16 June 2022
Primary completion13 March 2023
Estimated completion13 March 2023
Sites3 locations across India

Drugs / interventions tested

Conditions studied

Sponsor

Vedic Lifesciences Pvt. Ltd. — full company profile →

Who can join

Adults 30 to 60, any sex, with Oxidative Stress. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present clinical investigation has been proposed to further substantiate the evidence of the antioxidant and anti-inflammatory activity of the extract in the healthy adult population with BMI ranging from ≥25.0 kg/m2 and ≤ 34.9 kg/m2 . The antioxidant effect of the 56 days of oral administration of the extract (1000 mg/day) will be primarily assessed by change in the level of 8-isoprostane from baseline to the end of the study and the anti-inflammatory activity of the extract will be investigated by the change in the level of CRP and IL-6. In addition, the effect on lipid peroxidation and DNA damage will be assessed by serum level of MDA before and after 2 months of extract administration. Further, metabolic endotoxemia will be assessed by the change in the plasma level of lipopolysaccharides. Weight and waist circumference are included as secondary outcomes as the clinical indicators of reduction in oxidative stress and inflammation. Overweight and obesity significantly impact the health-related quality of life31 in the affected individuals and flavonoids have previously been shown to improve the quality of life in controlled clinical studies therefore, Investigator included health-related quality of life as a secondary objective of the study. The safety of the 2-month administration of the extract will be examined by a change in the vitals, liver, and kidney function biomarkers (SGOT, SGPT, ALP, and creatinine).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effect of SophorOx<sup>®</sup> on Oxidative Stress and Body Composition in Individuals with High BMI: A Randomized Controlled Trial.
    Roza JM, Srivastava S. · · 2024 · cited 1× · PMID 38854444 · DOI 10.2147/dmso.s452451

Verify or expand the search:

Other recruiting trials for Oxidative Stress

Currently open trials in the same condition.

Other Vedic Lifesciences Pvt. Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05404217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing